试验观察：癌症免疫治疗中的Toll样受体激动剂
Trial Watch: Toll-like receptor agonists in cancer immunotherapy.
作者信息
Smith Melody, García-Martínez Elena, Pitter Michael R, Fucikova Jitka, Spisek Radek, Zitvogel Laurence, Kroemer Guido, Galluzzi Lorenzo
机构信息
Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hematology and Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
出版信息
Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018.
Abstract
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.
摘要
Toll样受体（TLR）激动剂作为抗癌免疫疗法的免疫佐剂显示出治疗前景。迄今为止，三种TLR激动剂已获美国监管机构批准用于癌症患者。此外，在过去几年中，人们广泛研究了迄今仍处于实验阶段的TLR配体介导临床上有用的免疫刺激作用的潜力。在此，我们总结了TLR激动剂用于癌症治疗的最新临床前和临床进展。
相似文献
1
Trial Watch: Toll-like receptor agonists in cancer immunotherapy.试验观察：癌症免疫治疗中的Toll样受体激动剂
Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018.
2
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.试验观察：癌症治疗中使用Toll样受体激动剂进行免疫刺激
Oncoimmunology. 2015 Sep 2;5(3):e1088631. doi: 10.1080/2162402X.2015.1088631. eCollection 2016 Mar.
3
Trial watch: Toll-like receptor ligands in cancer therapy.研究观察： Toll 样受体配体在癌症治疗中的作用。
Oncoimmunology. 2023 Feb 17;12(1):2180237. doi: 10.1080/2162402X.2023.2180237. eCollection 2023.
4
Trial Watch: Toll-like receptor agonists in oncological indications.试验观察：肿瘤适应症中的Toll样受体激动剂
Oncoimmunology. 2014 Aug 1;3:e29179. doi: 10.4161/onci.29179. eCollection 2014.
5
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.试验观察：用于肿瘤适应症的实验性TLR7/TLR8激动剂
Oncoimmunology. 2020 Jul 21;9(1):1796002. doi: 10.1080/2162402X.2020.1796002.
6
Trial Watch: Toll-like receptor agonists for cancer therapy.试验观察：用于癌症治疗的 Toll 样受体激动剂
Oncoimmunology. 2013 Aug 1;2(8):e25238. doi: 10.4161/onci.25238. Epub 2013 Jun 10.
7
Toll-like receptor agonists in cancer therapy. Toll 样受体激动剂在癌症治疗中的应用。
Immunotherapy. 2009 Nov;1(6):949-64. doi: 10.2217/imt.09.70.
8
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.研究观察：美国食品和药物管理局批准的用于癌症治疗的 Toll 样受体激动剂。
Oncoimmunology. 2012 Sep 1;1(6):894-907. doi: 10.4161/onci.20931.
9
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.试验观察：用于癌症治疗的实验性 Toll 样受体激动剂。
Oncoimmunology. 2012 Aug 1;1(5):699-716. doi: 10.4161/onci.20696.
10
Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.抗体偶联物用于将 Toll 样受体 9 激动剂靶向递送至肿瘤组织。
PLoS One. 2023 Mar 13;18(3):e0282831. doi: 10.1371/journal.pone.0282831. eCollection 2023.
引用本文的文献
1
Improvement of the Anticancer Efficacy of PD-1/PD-L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies.PD-1/PD-L1阻断疗法抗癌疗效的改善：分子机制与治疗策略的进展
MedComm (2020). 2025 Jul 15;6(8):e70274. doi: 10.1002/mco2.70274. eCollection 2025 Aug.
2
Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers.靶向肿瘤相关巨噬细胞治疗实体器官癌症的新兴疗法。
Expert Opin Emerg Drugs. 2025 Jun;30(2):109-147. doi: 10.1080/14728214.2025.2504376. Epub 2025 May 25.
3
Toll-Like Receptor 4 and 8 are Overexpressed in Lung Biopsies of Human Non-small Cell Lung Carcinoma.Toll样受体4和8在人非小细胞肺癌肺活检组织中过表达。
Lung. 2025 Mar 1;203(1):38. doi: 10.1007/s00408-025-00793-8.
4
An anoikis-related signature predicts prognosis and immunotherapy response in gastrointestinal cancers.一种与失巢凋亡相关的特征可预测胃肠道癌症的预后和免疫治疗反应。
Front Immunol. 2025 Feb 6;16:1477913. doi: 10.3389/fimmu.2025.1477913. eCollection 2025.
5
Design, Synthesis, and Biological Evaluation of BODIPY-Caged Resiquimod as a Dual-Acting Phototherapeutic.作为双效光疗剂的硼二吡咯甲川笼形瑞喹莫德的设计、合成及生物学评价
J Med Chem. 2025 Feb 27;68(4):4561-4581. doi: 10.1021/acs.jmedchem.4c02606. Epub 2025 Feb 17.
6
Research progress on intratumoral microorganisms in renal cancer.肾癌瘤内微生物的研究进展
World J Urol. 2025 Jan 15;43(1):72. doi: 10.1007/s00345-024-05403-5.
7
Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide.DNA损伤修复途径中的功能性种系变异与接受替莫唑胺治疗的成年胶质瘤患者的生存改变有关。
Neuro Oncol. 2025 Jun 21;27(5):1385-1398. doi: 10.1093/neuonc/noae275.
8
Investigate the binding of pesticides with the TLR4 receptor protein found in mammals and zebrafish using molecular docking and molecular dynamics simulations.采用分子对接和分子动力学模拟研究哺乳动物和斑马鱼中 TLR4 受体蛋白与农药的结合。
Sci Rep. 2024 Oct 18;14(1):24504. doi: 10.1038/s41598-024-75527-6.
9
Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide.DNA损伤修复途径中的功能性种系变异与接受替莫唑胺治疗的成年胶质瘤患者的生存改变有关。
medRxiv. 2024 Oct 10:2023.10.13.23296963. doi: 10.1101/2023.10.13.23296963.
10
An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses.一种 TLR7/8 激动剂与 TGFβ 抑制剂的原位储库，可促进抗肿瘤免疫反应。
Nat Commun. 2024 Sep 3;15(1):7687. doi: 10.1038/s41467-024-50967-w.
本文引用的文献
1
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.阿特珠单抗单药治疗转移性非小细胞肺癌的安全性和临床活性：I 期研究的最终结果。
Eur J Cancer. 2018 Sep;101:201-209. doi: 10.1016/j.ejca.2018.06.031. Epub 2018 Aug 1.
2
Pembrolizumab effective in PD-L1-positive disease.帕博利珠单抗对PD-L1阳性疾病有效。
Nat Rev Urol. 2018 Nov;15(11):656. doi: 10.1038/s41585-018-0070-5.
3
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.晚期非小细胞肺癌患者接受阿特珠单抗联合铂类双药化疗的长期生存随访。
Eur J Cancer. 2018 Sep;101:114-122. doi: 10.1016/j.ejca.2018.06.033. Epub 2018 Jul 24.
4
Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.初诊 T1 高级别膀胱尿路上皮癌的治疗策略：新见解和更新建议。
Eur Urol. 2018 Nov;74(5):597-608. doi: 10.1016/j.eururo.2018.06.024. Epub 2018 Jul 13.
5
Vaccination-induced skin-resident memory CD8 T cells mediate strong protection against cutaneous melanoma.疫苗接种诱导的皮肤驻留记忆性CD8 T细胞介导对皮肤黑色素瘤的强大保护作用。
Oncoimmunology. 2018 Mar 19;7(7):e1442163. doi: 10.1080/2162402X.2018.1442163. eCollection 2018.
6
Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.基于抗CTLA-4的疗法在转移性黑色素瘤患者中引发了针对半乳糖凝集素-3的体液免疫。
Oncoimmunology. 2018 Mar 13;7(7):e1440930. doi: 10.1080/2162402X.2018.1440930. eCollection 2018.
7
Gr-1+ Cells Other Than Ly6G+ Neutrophils Limit Virus Replication and Promote Myocardial Inflammation and Fibrosis Following Coxsackievirus B3 Infection of Mice.Gr-1+ 细胞（非 Ly6G+ 中性粒细胞）限制病毒复制，并促进小鼠柯萨奇病毒 B3 感染后的心肌炎症和纤维化。
Front Cell Infect Microbiol. 2018 May 15;8:157. doi: 10.3389/fcimb.2018.00157. eCollection 2018.
8
Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.ARNAX 疫苗免疫疗法可在小鼠模型中诱导肿瘤特异性记忆 T 细胞和持久的抗肿瘤免疫。
Cancer Sci. 2018 Jul;109(7):2119-2129. doi: 10.1111/cas.13649. Epub 2018 Jun 16.
9
Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.树突状细胞激活增强了抗程序性死亡蛋白 1 介导的胶质母细胞瘤免疫治疗效果。
Oncotarget. 2018 Apr 17;9(29):20681-20697. doi: 10.18632/oncotarget.25061.
10
Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.双重检查点阻断的互补机制可扩展独特的T细胞库，并激活三阴性乳腺癌中的适应性抗肿瘤免疫。
Oncoimmunology. 2018 Jan 19;7(5):e1421891. doi: 10.1080/2162402X.2017.1421891. eCollection 2018.
Zotero 插件